Chargement en cours...
Evaluation for Potential Drug–Drug Interaction of MT921 Using In Vitro Studies and Physiologically–Based Pharmacokinetic Models
MT921 is a new injectable drug developed by Medytox Inc. to reduce submental fat. Cholic acid is the active pharmaceutical ingredient, a primary bile acid biosynthesized from cholesterol, endogenously produced by liver in humans and other mammals. Although individuals treated with MT921 could be adm...
Enregistré dans:
| Publié dans: | Pharmaceuticals (Basel) |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8308925/ https://ncbi.nlm.nih.gov/pubmed/34358080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14070654 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|